Specialty biotechnology company Gemelli Biotech has announced the launch of a blood test that measures anti-vinculin levels to help physicians identify the risk of gastrointestinal or vascular ...

Please provide your email address to receive an email when new articles are posted on . Nearly 10% of patients with systemic sclerosis had systemic sclerosis sine scleroderma, a subtype without skin ...

The anti-interleukin agent romilkimab showed significant benefits on skin fibrosis among patients with systemic sclerosis in a phase II trial, researchers reported. At week 24, the least squares mean ...

New research at ACR Convergence 2023, the American College of Rheumatology's (ACR) annual meeting, shows that patients with refractory juvenile systemic sclerosis improved significantly on nearly all ...

AMSTERDAM — For patients with diffuse cutaneous systemic sclerosis, an autoimmune disease for which there are few treatment options, lenabasum (JBT-101, Corbus Pharmaceuticals) shows potential, new ...

Systemic sclerosis -- or scleroderma that affects the skin and internal organs -, is one of the rarest autoimmune diseases, affecting roughly 100,000 people (primarily women) in the United ...

Angiotensin-converting enzyme (ACE) inhibitors are the mainstay of therapy for patients with systemic sclerosis in scleroderma renal crisis, however mortality remains high even in the post-ACE ...

Adding pirfenidone to mycophenolate mofetil shows no significant improvement in lung function compared with mycophenolate ...

For patients with systemic sclerosis, myopathy is a risk factor for worse outcomes and survival, according to a recent study. Patients with systemic sclerosis (SSc) as well as myopathy had more severe ...